Fig. 8: Patients with SERPING1-high levels exhibited remarkable benefits from immunotherapy.

A Correlation between immune score, stromal score, ESTIMATE score, and SERPING1 in the high and low SERPING1 group. The expression of SERPING1 in the high- and low-score groups was on the top, while the scores in the SERPING1-high and -low groups were on the right. B Satellite maps were used to represent the correlation between the four IPS scores and the expression of SERPING1. C Correlation analysis for SERPING1 and the expression of MHC family genes and immune checkpoints. D Difference in the relative abundance of immune cell infiltration in tumor microenvironment between the SERPING1-high and -low groups. Difference > 0 indicates that the immune cells were enriched in the SERPING1- high group and the column color represents the statistical significance of the difference. E Prognosis of the patients receiving immunotherapy (anti-CTLA-4) in the cohort of Nathanson (2017). F Proportion of patients responding to anti-PD-1 therapy in the SERPING1-high and low group from the cohort of PRJE23709. G Analysis of survival differences between SERPING1-high and low expression in different immunotherapy cohorts. HR < 1 in the volcano plot indicates that patients with SERPING1-high expression have a better prognosis than patients with SERPING1-low expression. H Predictive power of SERPING1 expression levels for efficacy in different immunotherapy cohorts. A larger value in the heatmap indicates greater predictive ability. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.